pdsbiotech.com (PDSB) Long-Term Debt to Capital Ratio

PDS Biotechnology is developing the Versamune system to combat HPV-related tumors, supported by the FDA. The long-term debt-to-equity ratio illustrates the issuer's financial stability, where the value of 0.00 represents the most recent figure. Business growth is bolstered by alliances with national health institutes, while an active pipeline ensures the imminent entry of breakthrough drugs into the pharmaceutical market.

For PDS Biotechnology, which develops protein vaccines amidst fierce competition from mRNA therapy, the long-term debt-to-equity trend serves as an indicator of financial stability. This metric is calculated as the ratio of liabilities with a maturity exceeding one year to the total shareholder equity. It determines the company's degree of reliance on external borrowings to fund R&D. Low leverage is critical for survival during the risky clinical trial phase, as it minimizes the risk of bankruptcy should there be a shift in technological leadership within oncology.